Clarisa R. Gracia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Clarisa R. Gracia has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Mary D. Sammel
Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
2 shared publications - Christine E. Hill-Kayser
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania
1 shared publication - Christopher B. Morse
15Obstetrics and Gynecology, Allegheny General Hospital, Pittsburgh, Pennsylvania
1 shared publication - Ellen W. Freeman
Laboratory of Plasma Studies, Cornell University 2 , Ithaca, New York 14853
1 shared publication George Kovalevsky
1 shared publication- Huifang A. Zhai
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania
1 shared publication
Latest Publications
- 18 December 2018
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 104 (5) , 1813-1822
Differential Rates of Change in Measures of Ovarian Reserve in Young Cancer Survivors Across the Reproductive Lifespan
Context Recent studies have examined level and rate of change of anti-mullerian hormone (AMH) for predicting time to menopause. Limited prospective, longitudinal data exists evaluating measures of ovarian reserve (MOR) in cancer survivors. Purpose Determine the rate of change of MOR in survivors (15-39 years) compared to similar-aged controls and compared to late reproductive-aged controls (40-50 years). Design Prospective cohort Setting Quaternary university hospital Participants Survivors at least 1 year from therapy completion, similar-aged controls, and late reproductive-aged controls. Interventions Annual visits with early follicular-phase hormone analysis and ultrasound. Main Outcome Measure Changes in AMH and antral follicle count (AFC) were modeled using random effects linear regression. Results 170 cancer survivors and 135 similar-aged controls had annual visits for an average of 38 months, while 71 late-reproductive aged controls were followed for an average of 24 months. In models adjusted for body mass index, time since cancer therapy (for survivors), and exogenous hormone use, the geometric mean AMH and AFC levels were lower in the survivors than similar-aged controls at all ages. After age 24.5 AMH and AFC declined in both groups at rates that were similar (p=0.78 for AMH, p=0.37 for AFC). Late-reproductive aged controls declined at a much more precipitous rate of 30% per year for AMH and 16% per year for AFC (p<0.01 compared to survivors). Conclusions Though survivors had lower levels of AMH and AFC at the time of enrollment, the rate of change of AMH and AFC is not significantly different than similar-aged controls.
- 18 December 2018
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 104 (5) , 1813-1822
Differential Rates of Change in Measures of Ovarian Reserve in Young Cancer Survivors Across the Reproductive Lifespan
Context Recent studies have examined level and rate of change of anti-mullerian hormone (AMH) for predicting time to menopause. Limited prospective, longitudinal data exists evaluating measures of ovarian reserve (MOR) in cancer survivors. Purpose Determine the rate of change of MOR in survivors (15-39 years) compared to similar-aged controls and compared to late reproductive-aged controls (40-50 years). Design Prospective cohort Setting Quaternary university hospital Participants Survivors at least 1 year from therapy completion, similar-aged controls, and late reproductive-aged controls. Interventions Annual visits with early follicular-phase hormone analysis and ultrasound. Main Outcome Measure Changes in AMH and antral follicle count (AFC) were modeled using random effects linear regression. Results 170 cancer survivors and 135 similar-aged controls had annual visits for an average of 38 months, while 71 late-reproductive aged controls were followed for an average of 24 months. In models adjusted for body mass index, time since cancer therapy (for survivors), and exogenous hormone use, the geometric mean AMH and AFC levels were lower in the survivors than similar-aged controls at all ages. After age 24.5 AMH and AFC declined in both groups at rates that were similar (p=0.78 for AMH, p=0.37 for AFC). Late-reproductive aged controls declined at a much more precipitous rate of 30% per year for AMH and 16% per year for AFC (p<0.01 compared to survivors). Conclusions Though survivors had lower levels of AMH and AFC at the time of enrollment, the rate of change of AMH and AFC is not significantly different than similar-aged controls.
- Open Access
- 21 May 2014
- Published by SAGE Publications in Journal of Adolescent and Young Adult Oncology
- Vol. 3 (2) , 96-99
Preserving Fertility in Adolescent Girls and Young Women Requiring Craniospinal Irradiation: A Case Report and Discussion of Options to Be Considered Prior to Treatment
Craniospinal irradiation (CSI) is associated with infertility risk for adolescent/young adult women. We explore two methods of reducing ovarian exposure: oophoropexy (surgical removal of the ovaries from the path of the X-ray beam) and proton therapy (to allow the beam to stop without exposing the ovaries/uterus). In the case discussed, oophoropexy followed by X-ray CSI reduced ovarian dose to that at which 50% of oocytes are expected to survive, and the patient appears to have viable oocytes; this technique did not reduce uterine dose. Proton therapy would have eliminated the ovarian and uterine dose and the need for oophoropexy.
- 21 May 2014
- Published by SAGE Publications in Journal of Adolescent and Young Adult Oncology
- Vol. 3 (2) , 96-99
Open AccessPreserving Fertility in Adolescent Girls and Young Women Requiring Craniospinal Irradiation: A Case Report and Discussion of Options to Be Considered Prior to Treatment
Craniospinal irradiation (CSI) is associated with infertility risk for adolescent/young adult women. We explore two methods of reducing ovarian exposure: oophoropexy (surgical removal of the ovaries from the path of the X-ray beam) and proton therapy (to allow the beam to stop without exposing the ovaries/uterus). In the case discussed, oophoropexy followed by X-ray CSI reduced ovarian dose to that at which 50% of oocytes are expected to survive, and the patient appears to have viable oocytes; this technique did not reduce uterine dose. Proton therapy would have eliminated the ovarian and uterine dose and the need for oophoropexy.
- 7 October 2013
- Published by Georg Thieme Verlag KG in Seminars in Reproductive Medicine
- Vol. 31 (06) , 427-436
What is Normal Ovarian Reserve?
While hormonal and ultrasonographic measures of ovarian reserve are often used to counsel patients about their fertility potential, normative data for these markers in the general population are lacking. Most studies are cross sectional and take place within specific subpopulations. Antral follicle count and anti-Mullerian hormone have been shown to be the best indicators of a woman's total follicular reserve. Ovarian volume, inhibin B, estradiol, and follicle-stimulating hormone are less helpful. Antral follicle count and anti-Mullerian hormone decrease with age and have been used to attempt to predict the length of the fertile window. Additional longitudinal data are needed for these biomarkers in populations of young, healthy, multiethnic women to assess for the presence of cofactors and determine the rate of age-related decline. Currently, these biomarkers are insufficient as predictors of fertility potential or advancement to menopause and no definitive determinations can be made about what constitutes “normal” levels of each measure.
- 7 October 2013
- Published by Georg Thieme Verlag KG in Seminars in Reproductive Medicine
- Vol. 31 (06) , 427-436
What is Normal Ovarian Reserve?
While hormonal and ultrasonographic measures of ovarian reserve are often used to counsel patients about their fertility potential, normative data for these markers in the general population are lacking. Most studies are cross sectional and take place within specific subpopulations. Antral follicle count and anti-Mullerian hormone have been shown to be the best indicators of a woman's total follicular reserve. Ovarian volume, inhibin B, estradiol, and follicle-stimulating hormone are less helpful. Antral follicle count and anti-Mullerian hormone decrease with age and have been used to attempt to predict the length of the fertile window. Additional longitudinal data are needed for these biomarkers in populations of young, healthy, multiethnic women to assess for the presence of cofactors and determine the rate of age-related decline. Currently, these biomarkers are insufficient as predictors of fertility potential or advancement to menopause and no definitive determinations can be made about what constitutes “normal” levels of each measure.
- 30 September 2002
- Published by Elsevier in Fertility and Sterility
- Vol. 78, S194
Is factor V leiden mutation (FVL) associated with recurrent pregnancy loss (RPL): a meta-analysis
- 30 September 2002
- Published by Elsevier in Fertility and Sterility
- Vol. 78, S194
Is factor V leiden mutation (FVL) associated with recurrent pregnancy loss (RPL): a meta-analysis
- 1 September 2002
- Published by Elsevier in Fertility and Sterility
- Vol. 78, S99
Decreased libido in women in the late reproductive years
- 1 September 2002
- Published by Elsevier in Fertility and Sterility
- Vol. 78, S99
Decreased libido in women in the late reproductive years